Victoria Socha

DocwireNews

Patients with chronic kidney disease 
(CKD) commonly experience abnormalities of mineral and bone metabolism, 
contributing significantly to increased rates of mortality and morbidity, 
including cardiovascular disease and fracture. The term chronic 
kidney-disease-mineral and bone disorder (CKD-MBD) encompasses disturbances of 
mineral metabolism, renal bone disease, and vascular calcification in 
combination with patient-level outcomes of fracture, cardiovascular disease, 
and mortality in patients with CKD.Phosphate binders, vitamin D 
analogues, and parathyroidectomy are standard of care for CKD-MBD. Treatment is 
complex and is not firmly evidence-based; further, there is potential for harm 
with current treatments. Conventional three times a week dialysis is often 
insufficient to attain negative phosphate balance and fewer than half of 
dialysis patients achieve levels suggested by several clinical practice guidelines. 
Low dietary protein intake and malnutrition can result from aggressive 
adherence to a low-phosphate diet and the large number of phosphate binder 
tablets required to control hyperphosphatemia creates high pill burden, 
increased disease intrusion, abdominal symptoms, and potential conflict with 
other medications.In the ACTIVE Dialysis (A Clinical 
Trial of Intensive Dialysis) study, extended hours dialysis reduced serum 
phosphate but did not cause changes in parathyroid hormone (PTH) or serum 
calcium. Researchers, led by Zhipeng Zhan, MD, and Brendon Smyth, MD, 
conducted a secondary analysis of data from the ACTIVE Dialysis trial to 
examine the impact of extended hours dialysis on CKD-MBD markers in 
prespecified patient groups, accounting for concurrent changes in non-dialytic 
CKD-MBD therapies. Results of the secondary analysis were reported online in BMC 
Nephrology [doi.org/11.1186/s12882-019-1438-3].The primary outcome of interest was 
the mean difference in each parameter between the extended (n=100) and standard 
dialysis arms (n=100), adjusted for confounding participant characteristics and 
for changes in associated non-dialytic therapies: total number of phosphate 
binders, use of calcitriol/alfacalcidol, dose of cinacalcet, and dialysate 
calcium. Secondary outcomes included interactions between subgroups derived 
from six pre-defined criteria and the unadjusted mean difference in parameters 
between treatment arms.A total of 200 participants were 
recruited from China (62.0%), Australia (29.0%), Canada, (5.5%), and New 
Zealand (3.5%). The groups were similar in concentrations of serum phosphate, 
corrected calcium, and intact PTH. In the standard arm, median total weekly 
dialysis hours during the study period was 12, compared with 24 in the extended 
arm. In the standard arm, use of hemodiafiltration was more common during the 
study period than in the extended arm (22.2% vs 14.2% of sessions); the 
difference did not reach statistical significance. There were no significant 
differences in dialysate concentrations of sodium, potassium, or calcium.During the study period, blood flow 
rates were lower in the extended arm compared with the standard arm (250 mL/min 
vs 280 mL/min). At 90.6% of study visits, dialysate flow rate was 500 mL/min 
and median flow rates did not differ (500 mL/min) (a small number of outlying 
values resulted in mean dialysate flow rates being lower in the extended arm). 
In the standard arm, one participant had a fracture and two had 
parathyroidectomies; in the extended arm, there was one fracture and one 
parathyroidectomy.Extended hours dialysis resulted in reduction 
in use of phosphate binders (&ndash;0.83 tablets per day; 95% confidence interval 
[CI], &ndash;1.16 to &ndash;0.04; P=.04). In adjusted analyses, there were no 
differences in type of phosphate binder, use of vitamin D, dose of cinacalcet, 
or dialysate calcium. Over the duration of the study, 
achievement of serum phosphate levels within the target range was more common 
in the extended arm (relative risk [RR], 1.21; 95% CI, 1.04-1.43; P=.016). 
There were no differences between the two groups in the proportion of patients 
who achieved target ranges for serum calcium (RR, 1.03; 95% CI, 0.93-1.14; P=.61) 
and PTH (RR, 1.09; 95% CI, 0.89-1.34; P=.40).Across the tested subgroups, the 
impact of extended hours dialysis on serum phosphate, calcium, and PTH was 
generally consistent. Exceptions were the significant interaction between the 
effect of treatment allocation on phosphate and both baseline level of PTH (P 
for interaction=.043) and dialysis location (P for interaction=.046), such that 
participants with high baseline PTH and dialyzing at an institution experienced 
a greater reduction in serum phosphate with extended hours dialysis. There was 
also a significant interaction between the effect of treatment allocation on 
PTH and baseline phosphate (P for interaction=.019); participants with 
low baseline serum phosphate had a small increase in PTH if assigned to 
extended hours dialysis.There were some limitations to the 
findings, including the relatively small cohort size, limiting the power of the 
study to detect subgroup differences; the short study duration; and the lack of 
serum levels of calcidiol (25-hydroxyvitamin D).In conclusion, the researchers said, 
&ldquo;The improvement in serum phosphate associated with extended hours hemodialysis 
was independent of changes in other CKD-MBD therapies and was consistent across 
a range of important patient subgroups. The observed differences in the impact 
of extended hours dialysis on phosphate seen in those with high baseline PTH or 
dialyzing in an institution, or on PTH in those with low phosphate require 
confirmation in larger studies.&rdquo;Takeaway Points<ol class="wp-block-list">
<li>Chronic kidney disease-mineral and 
bone disorder (CKD-MBD) is associated with changes in phosphate, calcium, and 
parathyroid hormone (PTH) in patients on hemodialysis. Researchers conducted an 
analysis of data from the ACTIVE Dialysis study that compared conventional 
dialysis&nbsp; (&le;18 h/week) with extended 
hours dialysis (&ge;24 h/week).</li>
<li>Phosphate binder use was reduced 
among patients assigned to extended hours dialysis; there was no difference in 
type of phosphate binder.</li>
<li>In adjusted analysis, there was an 
association between extended hours dialysis and lower phosphate; there was no significant 
change in serum calcium or PTH among patients in the extended hours arm 
compared with the standard arm.</li>
</ol>

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Extended Hours Dialysis Reduced Serum Phosphate Levels in Patients with CKD-MBD

Chronic Kidney Disease

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe